Evaluation of the serological response to booster vaccinationin in patients receiving autologous hematopoietic stem cell transplantation

INTERVENTION: Intervention 1: Intervention group 1: injection of one homologous booster dose of Pastocovac 4 weeks (±7 days) after receiving two doses of primary Pastocovac vaccine, that is injected intramuscularly 0.5 ml into the deltoid muscle. Intervention 2: Intervention group 2: injection of one heterologous booster dose of Sinopharm 4 weeks (±7 days) after receiving two doses of primary Pastocovac vaccine, that is injected intramuscularly 0.5 ml into the deltoid muscle. CONDITION: Condition 1: Multiple myeloma. Condition 2: Non‐Hodgkin lymphoma. Condition 3: Hodgkin lymphoma. Condition 4: Myelodysplastic syndrome. ; Multiple myeloma and malignant plasma cell neoplasms ; Hodgkin lymphoma ; Hodgkin lymphoma ; Myelodysplastic syndromes PRIMARY OUTCOME: SARS‐CoV‐2 antibody titers. Timepoint: before the start of the intervention and 4 weeks (±7 days) after the injection of the booster dose vaccine. Method of measurement: ChemoBind SARS‐CoV‐? IgG Test. SECONDARY OUTCOME: Probable Side effect: local pain, fever, fatigue, headache and sore throat. Timepoint: One week after vaccination. Method of measurement: Vaccine side effects checklist. INCLUSION CRITERIA: Patients who have undergone autologous hematopoietic stem cell transplantation Between 6 months and 12 months after transplantation They have received two initial doses of Pastocovac vaccine At least one month after receiving the second dose